PLK1 inhibition could be a common target for gastric adenocarcinoma [137], bladder cancer [138], colon cancer [139], [140], hepatocellular carcinoma [141], medullary thyroid carcinoma [142], esophageal cancer [143], pancreatic cancer [144] and in some types of non-Hodgkin lymphomas [145] and breast cancer [146]. This evidence concerns the gene PLK1 and urinary bladder cancer.